Medical device maker Smith & Nephew is facing a narrow path to its ambitious 2026 growth target, according to RBC Capital Markets. The investment bank maintained its 'sector perform' rating on the stock, cautioning that the company's third-quarter results will need to show a clear acceleration to close the gap to its roughly 6% underlying sales growth goal.
What's the Issue?
Smith & Nephew, which makes orthopedic implants, wound care products, and surgical equipment, has guided investors to expect around 3.5% growth in the first half of this year. But RBC argues that to reach the company's 2026 target, a significant pickup in the second half is essential. The bank points to two specific headwinds that could mechanically reduce growth by about 1 percentage point: China's volume-based procurement program, a government initiative that pushes down prices on medical devices, and changes to US Medicare payment rules affecting certain skin substitutes.
These headwinds are not new, but their persistence means Smith & Nephew must deliver stronger operational performance in the coming quarters. The company's Q3 update, due later this year, will be the first major checkpoint for investors to see if that acceleration is materializing.
Broader Context
Smith & Nephew operates in a competitive global medical device market, where pricing pressure from government buyers and hospital groups is a constant challenge. The company has been investing in new products and digital surgery tools to differentiate itself, but the near-term focus remains on execution. RBC's cautious stance echoes broader market sentiment that the stock's valuation already reflects some optimism, leaving little room for disappointment.
For context, other analysts have also highlighted the importance of Smith & Nephew's growth trajectory. The company's performance is closely watched as a bellwether for the medical device sector, which has seen mixed results amid varying hospital spending patterns and regulatory changes across regions.
What It Means for Investors
For everyday investors, RBC's analysis underscores that Smith & Nephew's stock may not offer a clear catalyst until there is more evidence of a growth pickup. The 'sector perform' rating suggests the bank sees the stock as fairly valued relative to its peers, meaning significant upside may depend on the company beating its own targets.
Investors should watch for the Q3 earnings report, which will provide the first concrete data on whether the second-half recovery is on track. Key metrics to monitor include revenue growth in the company's orthopedic and wound care divisions, as well as any updates on the impact of China's procurement program and US Medicare changes.
It's also worth noting that Smith & Nephew's 2026 target is ambitious, and the company faces headwinds that are partly outside its control. While the stock could benefit from a successful turnaround, RBC's analysis suggests that patience may be required. As always, investors should consider their own risk tolerance and portfolio diversification before making any decisions.
For more on how other companies are navigating similar challenges, see our coverage of Berenberg's take on CTP's logistics growth and UK firms' growth expectations hitting a 2025 low.
